FII Data: Stock Market Insights on 13 Sep 2024 -Patanjali Foods

Foreign Investment(buy/sell) Trends of Today’s: Global Events of Medi Assist Healthcare Services , Kopran .

Company Logo	Company	Client Name	Buy/Sell	Qty Traded	Price	Trader Name
	Medi Assist Healthcare Services	Aditya Birla Sun Life Mutual Fund	Buy	400K	635.00	Medimatter Health Management Private
	Kopran	Bofa Securities Europe Sa	Buy	251K	348.65	Na
	Patanjali Foods	Gqg Partners Emerging Markets Equity Fund	Buy	4M	1854.00	Patanjali Ayurved
	Supreme Infrastructure India	Hayyan Ali Malallah Al Lawati	Sell	176K	80.20	Na
	Edelweiss Financial Services	India Acorn Icav	Buy	5M	124.00	Edelweiss Employees Welfare Trust
	Jagsonpal Pharmaceuticals	Infinity Holdings	Sell	2M	400.00	Infinity Portfolio Holdings

The 400K shares of Medi Assist Healthcare Services have been purchased by the by Aditya Birla Sun Life Mutual Fund through Foreign Investments at a price of ₹635.00 per share and it is sold by Medimatter Health Management Private at a price of ₹635.00 per share.
The 251K shares of Kopran have been purchased by the by Bofa Securities Europe Sa through Foreign Investments at a price of ₹348.65 per share.
The 4M shares of Patanjali Foods have been purchased by the by Gqg Partners Emerging Markets Equity Fund through Foreign Investments at a price of ₹1854.00 per share and it is sold by Patanjali Ayurved at a price of ₹1854.00 per share.
The 176K shares of Supreme Infrastructure India have been sold by the by Hayyan Ali Malallah Al Lawati through Foreign Investments at a price of ₹80.20 per share.
The 5M shares of Edelweiss Financial Services have been purchased by the by India Acorn Icav through Foreign Investments at a price of ₹124.00 per share and it is sold by Edelweiss Employees Welfare Trust at a price of ₹124.00 per share.
The 2M shares of Jagsonpal Pharmaceuticals have been sold by the by Infinity Holdings through Foreign Investments at a price of ₹400.00 per share and it is purchased by Infinity Portfolio Holdings at a price of ₹400.00 per share.

The 3M shares of Edelweiss Financial Services have been purchased by the by Abu Dhabi Investment Authority through Foreign Investments at a price of ₹124.00 per share and it is sold by Edelweiss Employees Welfare Trust at a price of ₹124.00 per share.
The 660K shares of Edelweiss Financial Services have been purchased by the by Ashoka India Equity Investment Trust Plc through Foreign Investments at a price of ₹124.00 per share and it is sold by Edelweiss Employees Welfare Trust at a price of ₹124.00 per share.
The 5M shares of Edelweiss Financial Services have been purchased by the by India Acorn Icav through Foreign Investments at a price of ₹124.00 per share and it is sold by Edelweiss Employees Welfare Trust at a price of ₹124.00 per share.
The 2M shares of Jagsonpal Pharmaceuticals have been sold by the by Infinity Holdings through Foreign Investments at a price of ₹400.00 per share and it is purchased by Infinity Portfolio Holdings at a price of ₹400.00 per share.

Kopran Limited

The financial snapshot for Kopran Limited reveals a noteworthy performance this quarter. Net sales amounted to ₹1,394.37 million and total income was ₹1,420.63 million. The company's expenditure was ₹1,273.29 million, leading to a net profit of ₹110.95 million. Earnings per Share (EPS) for continuing operations were ₹2.30. The report also highlights other income of ₹26.26 million, finance costs of ₹21.82 million, and employee benefit expenses of ₹133.48 million. Depreciation and amortization costs were ₹38.74 million, while current and deferred taxes were ₹36.79 million and ₹-0.40 million, respectively. The total comprehensive income for the period stood at ₹111.41 million, with other comprehensive income net of taxes at ₹0.46 million.

With a market capitalization of ₹1,424 crore, the company’s stock is currently priced at ₹295. The historical trading range of the stock is ₹327 / 185. The P/E ratio is remarkably high at 24.0, suggesting a significant valuation. The book value stands at ₹102, and the dividend yield is 1.02%. The Return on Capital Employed (ROCE) is 13.8%, and the Return on Equity (ROE) is 11.0%. The debt-to-equity ratio is very low at 0.20, though the company shows a negative net cash flow of ₹0.69 crore. The Piotroski score is 6.00, with the Graham Number pegged at ₹168. The Price-to-Book (P/B) ratio of 2.90 highlights a premium valuation.

Patanjali Foods Limited

In the most recent financial analysis for Patanjali Foods Limited, key metrics demonstrate a solid performance. The net sales reached ₹71,730.60 million, with total income amounting to ₹72,023.59 million. Expenditure was recorded at ₹68,433.81 million, resulting in a net profit of ₹2,627.25 million. EPS figures for continuing operations are ₹7.26. Other notable figures include other income of ₹292.99 million, finance costs of ₹189.59 million, and employee benefit expenses totaling ₹1,172.78 million. Depreciation and amortization expenses were ₹569.62 million, with current tax at ₹652.14 million and deferred tax at ₹310.40 million. The total comprehensive income for the period was ₹2,584.04 million, and other comprehensive income net of taxes was ₹-43.21 million.

The company's market cap is ₹67,365 crore, with a stock price of ₹1,861. The historical stock range has been between ₹2,030 / 1,170. Its Price-to-Earnings (P/E) ratio of indicates a high valuation. The book value per share is ₹-129, and it has a dividend yield of 0.32%. The ROCE is 1.58% and ROE is %. With a very low debt-to-equity ratio of , the company is minimally leveraged. However, it reports a negative net cash flow of ₹120 crore. The Piotroski score of 7.00 and the Graham Number of ₹ show mixed financial indicators, while the Price-to-Book (P/B) ratio of suggests the stock is trading at a premium.

Supreme Infrastructure India Limited

The financial snapshot for Supreme Infrastructure India Limited reveals a noteworthy performance this quarter. Net sales amounted to ₹88.12 million and total income was ₹89.18 million. The company's expenditure was ₹-3.00 million, leading to a net profit of ₹-3.00 million. Earnings per Share (EPS) for continuing operations were ₹-119.54. The report also highlights other income of ₹1.07 million, finance costs of ₹-3.00 million, and employee benefit expenses of ₹-13.53 million. Depreciation and amortization costs were ₹-28.21 million, while current and deferred taxes were ₹0.00 million and ₹0.00 million, respectively. The total comprehensive income for the period stood at ₹-3.00 million, with other comprehensive income net of taxes at ₹0.00 million.

Valued at ₹166 crore, the company's stock trades at ₹64.6, with historical highs and lows of ₹117 / 22.6. The P/E ratio of reflects a high stock valuation. The book value is ₹-1,895, and the dividend yield is 0.00%. ROCE is at %, and ROE is %. The company’s minimal debt-to-equity ratio of contrasts with its negative net cash flow of ₹-4.81 crore. The Piotroski score is 4.00, and the Graham Number of ₹ provides insight into the stock’s valuation. The Price-to-Book (P/B) ratio of indicates a premium valuation.

Edelweiss Financial Services Limited

For Edelweiss Financial Services Limited, the latest financial data showcases impressive results. The company reported net sales of ₹29,673.00 million and total income of ₹30,266.20 million for the quarter. Expenditure was ₹28,087.30 million, resulting in a net profit of ₹2,030.80 million. EPS for continuing operations was ₹1.88. Additional financial details include other income of ₹593.20 million, finance costs of ₹7,177.90 million, and employee benefit expenses of ₹3,477.00 million. Depreciation and amortization expenses were ₹331.90 million. Current tax was ₹519.50 million and deferred tax amounted to ₹-371.40 million. Total comprehensive income for the period was ₹3,323.20 million, with other comprehensive income net of taxes at ₹1,292.40 million.

Valued at ₹11,160 crore, the company's stock trades at ₹118, with historical highs and lows of ₹125 / 52.0. The P/E ratio of 26.0 reflects a high stock valuation. The book value is ₹50.5, and the dividend yield is 1.27%. ROCE is at 11.5%, and ROE is 7.31%. The company’s minimal debt-to-equity ratio of 4.27 contrasts with its negative net cash flow of ₹-373 crore. The Piotroski score is 7.00, and the Graham Number of ₹71.8 provides insight into the stock’s valuation. The Price-to-Book (P/B) ratio of 2.34 indicates a premium valuation.

Jagsonpal Pharmaceuticals Limited

The financial snapshot for Jagsonpal Pharmaceuticals Limited reveals a noteworthy performance this quarter. Net sales amounted to ₹614.39 million and total income was ₹628.83 million. The company's expenditure was ₹524.88 million, leading to a net profit of ₹53.29 million. Earnings per Share (EPS) for continuing operations were ₹1.94. The report also highlights other income of ₹14.44 million, finance costs of ₹2.15 million, and employee benefit expenses of ₹147.39 million. Depreciation and amortization costs were ₹10.72 million, while current and deferred taxes were ₹15.87 million and ₹1.94 million, respectively. The total comprehensive income for the period stood at ₹52.81 million, with other comprehensive income net of taxes at ₹-0.48 million.

Currently valued at ₹959 crore, the company's stock price is ₹362. It has seen a price range of ₹515 / 270 over time. The stock's Price-to-Earnings (P/E) ratio is notably high at 42.7, implying a strong valuation. The book value per share is ₹70.9 and the dividend yield is 1.38%. ROCE is recorded at 17.0%, and ROE stands at 13.0%. The company maintains a very low debt-to-equity ratio of 0.05, though it has a negative net cash flow of ₹1.71 crore. The Piotroski score of 6.00 and the Graham Number of ₹116 suggest some caution, while the Price-to-Book (P/B) ratio of 5.11 reflects a premium valuation.

Join our telegram for more updates

Stay Updated with Our YouTube Videos